Sahaj Madhav is Director of Business Development in the Business Development group at Amgen. He is part of the transactions team, responsible for corporate development activities that include strategic collaborations such as the multi-target research collaboration with Generate Biomedicines announced in 2022 (potential transaction value of $1.9B plus future royalties), M&A, licensing/out-licensing activities, and equity investments. Sahaj recently led a number of outbound transactions to create new companies NewAmsterdam Pharma, Vigil Neuroscience, and Neumora Therapeutics (formed by Forbion, Atlas Ventures and Arch Venture Partners) respectively.  He led the acquisition of Rodeo Therapeutics (acquired for up to $721M) and played an integral role in the $13.4B asset acquisition of Otelza® from BMS/Celgene. Sahaj previously held roles on the valuation team in Business Development, as a U.S. revenue planner for Prolia® & EVENITY® and supporting the strategic financial and accounting analysis related to Amgen’s restructuring in 2014.  Sahaj holds a BS degree in Chemical Engineering from UCLA and an MBA from the Tepper School of Business at Carnegie Mellon.